ResMed

When researching ResMed, analysts typically begin with its Health Care sector positioning and Health Care Equipment industry dynamics. ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

The company reports trailing twelve-month revenue of $2.96B and net income of $398.73M. Key metrics include a return on equity of 6.1%, a debt-to-equity ratio of 0.35.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for RMD to support both active traders and long-term investors.